The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

Israel has also developed its own antibody compound, joining countries like America and Korea that are also studying monoclonal antibody therapy for COVID-19 patients. Visit BGR’s homepage for ...

Researchers continue to learn more about COVID-19’s long-term impact on our bodies. Now they’re looking into the link between the virus and erectile dysfunction (ED). That’s when a person ...

Almost $20 million was mistakenly paid to businesses and commercial landlords that were not eligible for grants during COVID-19, and the Victorian government is still writing off the losses.

NEW YORK, April 9 (Reuters) - A violent U.S. Treasury selloff, evoking the COVID-era "dash for cash," has reignited fears of fragility in the world’s biggest bond market. The $29-trillion ...